When exploring the predictive capability of these amplified genes, UBE2T expression levels were found significantly increased in TNBC patients not achieving pCR after neoadjuvant chemotherapy, whereas UBE2C and BIRC5 expression were higher in luminal A patients with tumor relapse within 5 years of endocrine therapy or chemotherapy. The gene discussed is UBE2T; the disease is neoplasm.